Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression
Xingyuan Xu, Longyun Ye, Qi Zhang, Hang Shen, Shanshan Li, Xiaoyu Zhang, Mao Ye, Tingbo Liang – 7 April 2021
Biological Nanotherapeutics for Liver Disease
Julia Driscoll, Cody Wehrkamp, Yu Ota, Jonathan N. Thomas, Irene K. Yan, Tushar Patel – 6 April 2021 – Extracellular vesicles (EVs) are a heterogeneous group of biological nano‐sized vesicles that are released from cells and contribute to intercellular communication. Emerging knowledge about their biogenesis, composition, release, and uptake has resulted in broad interest in elucidating their potential roles in disease pathophysiology.
New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer
Xiaoxiao Jiang, Hui Qian, Wen‐Xing Ding – 6 April 2021
Therapeutic Potential of G Protein‐Coupled Receptors Against Nonalcoholic Steatohepatitis
Dating Sun, Xia Yang, Bin Wu, Xiao‐Jing Zhang, Hongliang Li, Zhi‐Gang She – 6 April 2021
HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV‐Related HCC Through Reciprocal Regulation With Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 3
Wen‐bin Ding, Meng‐chao Wang, Jian Yu, Gang Huang, Da‐peng Sun, Lei Liu, Jia‐ning Zhang, Yuan Yang, Hui Liu, Wei‐ping Zhou, Fu Yang, Sheng‐xian Yuan – 6 April 2021
Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer‐Associated Fibroblasts Formed After Chronic Liver Injuries
Shan‐Shan Wang, Xinyu Thomas Tang, Minghui Lin, Jia Yuan, Yi Jacky Peng, Xiujuan Yin, GuoGuo Shang, Gaoxiang Ge, Zhenggang Ren, Bo O. Zhou – 4 April 2021
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia
Yi Niu, Ziyou Lin, Arabella Wan, Lei Sun, Shijia Yan, Heng Liang, Siyue Zhan, Dongshi Chen, Xianzhang Bu, Peiqing Liu, Ceshi Chen, Weiling He, Xiongbin Lu, Guohui Wan – 3 April 2021
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study
Tracey G. Simon, Bjorn Roelstraete, Rajani Sharma, Hamed Khalili, Hannes Hagström, Jonas F. Ludvigsson – 2 April 2021
Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors
Jacinth Wing‐Sum Cheu, Carmen Chak‐Lui Wong – 2 April 2021 – Hepatocellular carcinoma (HCC) is one of the deadliest cancers because of late symptom manifestation leading to delayed diagnosis, which limits patients with HCC in terms of receiving curative surgical treatment. There are only a few therapeutic options for patients with advanced HCC. The emergence of immune checkpoint inhibitors (ICIs) brings HCC treatment to a stage at which nivolumab, an anti–programmed cell death protein 1 monoclonal antibody, achieves a 20% response rate.
Heterozygosity of the Alpha 1‐Antitrypsin Pi*Z Allele and Risk of Liver Disease
Aaron Hakim, Matthew Moll, Dandi Qiao, Jiangyuan Liu, Jessica A. Lasky‐Su, Edwin K. Silverman, Silvia Vilarinho, Z. Gordon Jiang, Brian D. Hobbs, Michael H. Cho – 2 April 2021 – The serpin family A member 1 (SERPINA1) Z allele is present in approximately one in 25 individuals of European ancestry. Z allele homozygosity (Pi*ZZ) is the most common cause of alpha 1‐antitrypsin deficiency and is a proven risk factor for cirrhosis. We examined whether heterozygous Z allele (Pi*Z) carriers in United Kingdom (UK) Biobank, a population‐based cohort, are at increased risk of liver disease.